Skip to main content
SpringerLink
Log in

Guar Gum-Based Sustained Release Diltiazem

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. This study was performed to examine the use of guar gum to sustain the release of diltiazem under in vitro and in vivo conditions.

Methods. Guar gum tablet formulations were prepared and evaluated under a variety of in vitro dissolution conditions. The formulations, along with Dilacor XR®, were administered to a group of eight fasted, healthy volunteers in a four period crossover study.

Results. Varying the lot of guar gum as well as using guar from different suppliers had little effect on diltiazem dissolution. Also, dissolution of diltiazem from guar gum tablets was essentially independent of stir speed under normal conditions (USP Apparatus II). The stability of guar-based formulations under stressed conditions (40°C/75% relative humidity for 3 months) was also established. All four formulations gave similar plasma concentrations over time in the healthy volunteers pharmacokinetic study.

Conclusions. Guar gum-based matrix tablets represent a simple and economical alternative to existing diltiazem sustained release dosage forms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. A. M. Sakr and H. M. Elsabbagh. Correlation of water absorption with the disintegration effectiveness of guar gum. Pharm. Ind. 37:457-459 (1975).

    Google Scholar 

  2. E. M. Rudnic, C. T. Rhodes, J. F. Bavitz, and J. B. Schwartz. Some effects of relatively low levels of eight tablet disintegrants on a direct compression system. Drug Dev. Ind. Pharm. 7:347-358 (1981).

    Google Scholar 

  3. M. Z. Iqbal, M. Amin, and N. A. Muzaffar. Comparative evaluation of guar gum as disintegrating agent. J. Pharmacy 1:17-34 (1979).

    Google Scholar 

  4. L. E. Eatherton, P. E. Platz, and F. P. Cosgrove. Drug Standards 23:42-47 (1955).

    Google Scholar 

  5. W. Feinstein and A. J. Bartilucci. Comparative study of selected disintegrating agents. J. Pharm. Sci. 55:332-334 (1966).

    PubMed  Google Scholar 

  6. H. M. Elsabbagh, A. M. Sakr, and S. E. Abd-Elhadi. Effect of guar gum on the dissolution rate of ephedrine hydrochloride and sulphadimidine tablets. Pharmazie 33:730-731 (1978).

    PubMed  Google Scholar 

  7. P. J. Waaler, M. Anderson, C. Graffner, and B. W. Muller. Optimization of a matrix tablet formulation using a mixture design. Acta Pharm. Nord. 4:167-170 (1992).

    Google Scholar 

  8. H. E. Huber and G. L. Christenson. Utilization of hydrophilic gums for the control of drug substance release from tablet formulations II. Influence of tablet hardness and density on dissolution behavior. J. Pharm. Sci. 57:164-166 (1968).

    PubMed  Google Scholar 

  9. H. L. Bhalla and Y. D. Sanzgiri. An improved controlled release tablet of salbutamol sulphate. Indian J. Pharm. Sci. 49:22-25 (1987).

    Google Scholar 

  10. S. K. Baveja, K. V. Ranga Rao, and J. Arora. Chemical investigations of some galactomannan gums as matrix tablets for sustained drug delivery. Ind. J. Pharm. Sci. 30B:133-137 (1991).

    Google Scholar 

  11. H. L. Bhalla and S. O. Gulati. Sustained release theophylline tablets. Indian Drugs 24:338-342 (1987).

    Google Scholar 

  12. P. J. Waaler, C. Graffner, and B. W. Muller. Optimization of a matrix tablet formulation using a mixture design. Acta Pharm. Nord. 4:9-16 (1992).

    PubMed  Google Scholar 

  13. P.J. Waaler, K. Arnesen, C. Graffner, and B. W. Muller. Optimization of the amount of xanthan gum and guar gum in a matrix tablet formulation using a central composite design. Acta Pharm. Nord. 4:291-296 (1992).

    Google Scholar 

  14. P. J. Waaler, C. Graffner, and B. W. Muller. Biopharmaceutical studies of naftidrofuryl in hydrocolloid matrix tablets. Int. J. Pharm. 87:229-237 (1992).

    Google Scholar 

  15. K. Yu, D. Wong, J. Parasrampuria, and D. R. Friend. Guar Gum. In: Analytical Profiles of Drug Substances and Excipients, Vol. 24, H. G. Brittain, Ed., Academic Press, Orlando, Florida, pp. 397-442 (1996).

    Google Scholar 

  16. A. M. Goldstein, E. Alter, and J. K. Seamam. Guar gum In: Industrial gums, polysaccharides and their derivatives, 2nd ed. New York, NY: Academic Press.: pp. 303-321, (1973).

    Google Scholar 

  17. D. R. Friend, S. A. Altaf, K. L. Yu, and M. S. Gebert. Development of a zero-order nifedipine dosage form using COSRx technology. Proc. Int. Sym. Control. Rel. Bioact. Mat. 24:311-312 (1997).

    Google Scholar 

  18. M. S. Gebert and D. R. Friend. Purified guar galactomannan as an improved pharmaceutical excipient. Pharm. Develop. Tech.(1998) in press.

  19. M. S. Gebert, J. Parasrampuria, and D. R. Friend. Purified galactomannan as an improved pharmaceutical excipient. Pharm. Res. 13:S180 (1996).

    Google Scholar 

  20. F. Langenbucher. Parametric representation of dissolution-rate curves by the RRBSW distribution. Pharm. Ind. 38:472-477 (1976).

    Google Scholar 

  21. S. Bolton. Statistical Inference: Estimation and Hypothesis Testing, Pharmaceutical Biostatistics, Marcel Dekker, USA, pp. 105-161 (1984).

  22. R. Bodmeier, X. Guo, R. E. Sarabia, and P. F. Skultety. The Influence of Buffer Species and Strength on Diltiazem HCl Release from Beads Coated with the Aqueous Cationic Polymer Dispersions, Eudragit RS. RL 30D. Pharm. Res. 13:52-56 (1996).

    PubMed  Google Scholar 

  23. G. A. McClelland, S. Sutton, K. Engle, and G. M. Zentner. The solubility-modulated osmotic pump: in vitro/in vivo release. Pharm. Res. 8:88-92 (1991).

    PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Syed A. Altaf

    Present address: Gilead Sciences, Foster City, California, 94404

  2. Karen Yu

    Present address: Shaman Pharmaceuticals, Inc., South San Francisco, California, 94080

  3. Jagdish Parasrampuria

    Present address: Genelabs, Redwood City, California, 94063

Authors and Affiliations

  1. CIBUS Pharmaceutical, Inc., P.O. Box 1226, Menlo Park, California, 94026-1226

    Syed A. Altaf, Karen Yu, Jagdish Parasrampuria & David R. Friend

Authors
  1. Syed A. Altaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jagdish Parasrampuria
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David R. Friend
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Altaf, S.A., Yu, K., Parasrampuria, J. et al. Guar Gum-Based Sustained Release Diltiazem. Pharm Res 15, 1196–1201 (1998). https://doi.org/10.1023/A:1011931622536

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011931622536

Search

Navigation